Lukas Hainz

The pharmaceutical landscape is currently witnessing a massive transformation as Eli Lilly and Company accelerates its dominance by acquiring Engage Bio, a San Carlos-based firm specializing in non-viral genetic medicine. This strategic move, valued at approximately $202 million including

The realization that a physical trait used for security might be permanently compromised represents a fundamental shift in the landscape of digital personal safety and corporate accountability. While a stolen credit card number or a leaked password can be invalidated with a few keystrokes, the

The profound disconnect between Africa’s clinical research capacity and its disproportionate disease burden represents one of the most significant healthcare challenges of the modern era. While the continent currently accounts for approximately twenty-five percent of the global disease burden, it

The pharmaceutical industry has long grappled with the overwhelming complexity of human biology, where the cost and time required to bring a single therapeutic candidate to market often exceed the financial capabilities of all but the largest global entities. Traditional drug discovery has

The landscape of healthcare technology in Great Britain is undergoing a seismic shift as the Medicines and Healthcare products Regulatory Agency (MHRA) moves to replace aging statutes with the Medical Devices (Amendment) Regulations 2026. This comprehensive legislative overhaul, unveiled on May 8,

The standard medical approach of prescribing treatments based on a single laboratory test or a solitary physical examination is rapidly losing its relevance in an era defined by high-resolution data and continuous monitoring. While the industry has long chased the promise of precision medicine,

The intersection of institutional capital and essential human services has reached a new fever pitch as major real estate investment managers pivot toward recession-resistant sectors that promise long-term stability. Clarion Partners, a prominent subsidiary of Franklin Templeton, recently executed

For nearly nine million people in the United States living with the long-term debilitating effects of a stroke, the transition from acute clinical care to daily life often represents a plateau in physical recovery that previously seemed impossible to overcome. Mobia Medical recently made a

The long-held biological dogma that gene-editing machinery must rely on fragile RNA strands to find its target has finally been dismantled by a pioneering shift toward DNA-guided navigation. For years, the scientific community accepted the inherent instability of RNA as a necessary trade-off for

Ivan Kairatov brings a wealth of specialized knowledge to the table, having spent years at the intersection of biopharmaceutical innovation and clinical strategy. As an expert in drug development, he has navigated the complex regulatory landscapes that define the success or failure of orphan drug